Personalizing bladder treatment: could your other pills determine which drug works best?

NCT ID NCT07711808

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study compares two common medications for overactive bladder (OAB): solifenacin, which blocks nerve signals in the bladder, and mirabegron, which helps the bladder muscle relax. Researchers want to see if a person's 'anticholinergic burden'—the combined effect of other medications that also block those nerve signals—affects how well each drug works. Adults with newly diagnosed OAB who have not yet been treated will take one of the two drugs for two months, and their symptom improvement will be tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
solifenacin or mirabegron
What this could lead to
If successful, this study could help doctors choose the most effective first-line OAB treatment based on a person's existing medications, improving symptom relief and quality of life.
What could go wrong
This is a relatively small, short-term study (2 months) and results may not apply to everyone. The findings depend on accurate measurement of anticholinergic burden, which can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERACTIVE BLADDER (OAB) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.